A cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BV

被引：0
|
作者：
Morlock, Robert
Yu, Elaine
Ray, Joshua
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Genentech Inc, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
417
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Effectiveness and safety in very elderly patients treated by bevacizumab (BV) plus chemotherapy in first-line therapy of metastatic colorectal cancer: Results of ETNA, a French cohort study
    Smith, D.
    Rouyer, M.
    Noize, P.
    Lassalle, R.
    Bernard, O.
    Burki, F.
    Guichard, P.
    Ravaud, A.
    Moore, N.
    Fourrier-Raglat, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [42] Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).
    Cremolini, Chiara
    Loupakis, Fotios
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuki, Takeru
    Schirripa, Marta
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Masi, Gianluca
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Ronzoni, Monica
    Maus, Martin Karl Herbert
    Bocci, Guido
    Tonini, Giuseppe
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] PRODIGE 20: Bevacizumab plus chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)-A randomized phase II trial.
    Aparicio, Thomas
    Bouche, Olivier
    Francois, Eric
    Maillard, Emilie
    Kirscher, Sylvie
    Taieb, Julien
    Etienne, Pierre-Luc
    Faroux, Roger
    Khemissa, Faiza
    El Hajbi, Farid
    Locher, Christophe
    Rinaldi, Yves
    Lecomte, Thierry
    Lavau-Denes, Sandrine
    Baconnier, Mathieu
    Oden-Gangloff, Alice
    Genet, Dominique
    Paillaud, Elena
    Retornaz, Frederic
    Bedenne, Laurent
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress
    Wainberg, Z.
    Wang, L.
    Yue, H.
    Motwani, M.
    Kasichayanula, S.
    Blaney, M.
    Naumovski, L.
    Strickler, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [45] BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT
    Osterlund, P.
    Alonso-Orduna, V.
    Schlichting, C.
    Andre, T.
    Sastre, J.
    Greil, R.
    Kubicka, S.
    Reyes-Rivera, I.
    McCall, B.
    Van Cutsem, E. J. D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 195 - 195
  • [46] Bevacizumab improves outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) independent of baseline risk.
    Kabbinavar, F.
    Zurlo, A.
    Irl, C.
    Hurwitz, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 155S - 155S
  • [47] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Kiyoaki Sugiura
    Yuki Seo
    Takayuki Takahashi
    Hideyuki Tokura
    Yasuhiro Ito
    Motomu Tanaka
    Norihiro Kishida
    Yusuke Nishi
    Yoshihiko Onishi
    Hikaru Aoki
    [J]. BMC Gastroenterology, 21
  • [48] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Sugiura, Kiyoaki
    Seo, Yuki
    Takahashi, Takayuki
    Tokura, Hideyuki
    Ito, Yasuhiro
    Tanaka, Motomu
    Kishida, Norihiro
    Nishi, Yusuke
    Onishi, Yoshihiko
    Aoki, Hikaru
    [J]. BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [49] Post hoc safety and effectiveness analysis of aflibercept plus FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE
    Cartwright, Thomas H.
    Fakih, Marwan
    Garcia-Alfonso, Pilar
    Linke, Zdenek
    Ruiz Casado, Ana
    Polo Marques, Eduardo
    Picard, Pascaline
    Celanovic, Marina
    Singh, Arvind Rup
    Salinardi, Taylor
    Chau, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] EFFICACY AND SAFETY OF TREATMENT WITH BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV plus CT: AGE SUBGROUP ANALYSIS FROM A RANDOMISED PHASE III INTERGROUP STUDY (ML18147)
    Bouche, O.
    Steffens, C.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Osterlund, P.
    von Moos, R.
    Reyes-Rivera, I.
    Sersch, M. A.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 190 - 191
12345